You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Researchers presented interim results from the pilot PEER study of Aromasin, leuprolide, and Keytruda for HR-positive, HER2-negative advanced breast cancer.
The firm presented data at the AACR annual meeting that demonstrates its approach to treating HER2-positive solid cancers with engineered CAR macrophages.
A recent study suggests the lack of diversity in public databases may affect the accuracy of TMB scores and lead to inappropriate treatment for racial minorities.
The autologous, anti-BCMA CAR T-cell therapy may be the first to garner FDA approval for multiple myeloma patients but competing products may soon catch up.
Researchers are increasingly arguing that the tissue-agnostic approval was too broad, and that tumor mutational burden is only a biomarker of response to immunotherapy in a handful of cancer types.
The firm will collect multi-omics data from GBM patients and use its AI platform to home in on biomarkers of response to BPM31510.
The joint venture will use Veraxa Biotech's high-throughput technology to select antibodies against Indivumed's targets, beginning in colorectal and lung cancers.
The rate at which NGS-based algorithms generate obsolete trial matches is a system-wide information shortcoming, not a reflection of the tests themselves.
Medicare patients on FDA-approved cancer treatments in the real world do not live as long as patients in pivotal clinical trials, according to an MSK analysis.
The company's lead candidate lacutamab is moving into the second part of a Phase II trial for biomarker-defined cutaneous T-cell lymphoma patients.